Vasogen down on Celacade Phase III

Vasogen (TSX:VAS; VSGN) was off C$1.37 (74%) to C$0.48 on Monday after its Celacade ex vivo immune modulation therapy missed the primary endpoint in the Phase III ACCLAIM trial to treat chronic heart ...